-
Mashup Score: 8
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet-
We are excited to announce a new @CancerResrch publication in @MDPI Journal Diagnostics evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of #ctDNA in oncology drug development. https://t.co/FNpVn2BWrf #ctDNAFriends https://t.co/W1MfWt9KPY
-
-
Mashup Score: 8
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet-
We are excited to announce a new @CancerResrch publication in @MDPI Journal Diagnostics evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of #ctDNA in oncology drug development. https://t.co/FNpVn2BWrf #ctDNAFriends https://t.co/W1MfWt9KPY
-
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 3 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 3 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 3 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 3 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 3 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Join our Cloud HD Video Meeting - 3 day(s) ago
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution used around the world in board, conference, huddle, and training rooms, as well as executive offices and classrooms. Founded in 2011, Zoom helps businesses and organizations bring their teams together in a frictionless environment to get more done. Zoom is a publicly traded company headquartered in San Jose, CA.
Source: focr-org.zoom.usCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Join our Cloud HD Video Meeting - 3 day(s) ago
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution used around the world in board, conference, huddle, and training rooms, as well as executive offices and classrooms. Founded in 2011, Zoom helps businesses and organizations bring their teams together in a frictionless environment to get more done. Zoom is a publicly traded company headquartered in San Jose, CA.
Source: focr-org.zoom.usCategories: General Medicine News, Onc News and JournalsTweet
We are excited to announce a new @CancerResrch publication in @MDPI Journal Diagnostics evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of #ctDNA in oncology drug development. https://t.co/FNpVn2BWrf #ctDNAFriends https://t.co/W1MfWt9KPY